New sinusoidal pump for transferring syrups, oils, creams and gels
Watson-Marlow's new Certa Plus sinusoidal pump provides a sustainable solution for shear sensitive, viscous pharmaceutical products.
Watson-Marlow Fluid Technology Group has launched its new Certa Plus pump series to provide sustainable, high-quality, versatile fluid management for the pharmaceutical industry.
Compared with conventional lobe pumps, the new sinusoidal Certa Plus technology offers pharmaceutical manufacturers lower shear, lower power consumption, full traceability, and ultimate cleanability when transferring syrups, oils, creams and gels.
Certa Plus provides virtually pulsation-free product flow with no need for ancillary dampeners. This improves both flow meter accuracy and heat exchanger efficiency. The low shear handling minimises the temperature increase of the pumped liquid, as well as improving batch consistency and final product quality.
The new pump series is capable of transferring and handling a wide range of challenging products from syrups and sugar solutions to lozenge products.
Its continuous flow and high suction support the efficient manufacture of pastille products. Syrup and sugar solutions can also be processed with ease as the seal flush reduces the risk of sugar-based products drying out at the seal.
Across pharmaceutical applications, varying temperatures result in products with varying viscosities. For example, in the production of suppositories, pumping at lower temperature means an increased viscosity of the product. The powerful suction of the Certa Plus handles both low viscous liquids such as oils, and high viscous products, such as creams and gels, with ease.
Clean in place capabilities enable ease of cleaning and allow the pump to be easily integrated into an aseptic fluid path. The pump can then be wet cleaned without dismantling and is steam sterilisable and bacteria-tight to remove the risk of residuals and contamination. Certa Plus has full aseptic certification (EHEDG Type EL Class I and EHEDG Type EL Aseptic Class I) and all components are made of FDA and USP Class VI certified raw materials.
The pump also offers an energy-efficient alternative, requiring up to 50% less power than lobe or circumferential piston pumps, greatly reducing electricity use and hence carbon footprint.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance